VYNE vs. BOLT, EYEN, CARA, UNCY, NXTC, LEXX, DRRX, JAN, CASI, and SNSE
Should you be buying VYNE Therapeutics stock or one of its competitors? The main competitors of VYNE Therapeutics include Bolt Biotherapeutics (BOLT), Eyenovia (EYEN), Cara Therapeutics (CARA), Unicycive Therapeutics (UNCY), NextCure (NXTC), Lexaria Bioscience (LEXX), DURECT (DRRX), JanOne (JAN), CASI Pharmaceuticals (CASI), and Sensei Biotherapeutics (SNSE). These companies are all part of the "pharmaceutical preparations" industry.
VYNE Therapeutics (NASDAQ:VYNE) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.
Bolt Biotherapeutics received 56 more outperform votes than VYNE Therapeutics when rated by MarketBeat users. Likewise, 68.38% of users gave Bolt Biotherapeutics an outperform vote while only 58.54% of users gave VYNE Therapeutics an outperform vote.
In the previous week, VYNE Therapeutics had 10 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 13 mentions for VYNE Therapeutics and 3 mentions for Bolt Biotherapeutics. Bolt Biotherapeutics' average media sentiment score of 1.26 beat VYNE Therapeutics' score of 0.65 indicating that Bolt Biotherapeutics is being referred to more favorably in the news media.
Bolt Biotherapeutics has a net margin of -878.58% compared to VYNE Therapeutics' net margin of -6,874.47%. Bolt Biotherapeutics' return on equity of -51.18% beat VYNE Therapeutics' return on equity.
VYNE Therapeutics has higher earnings, but lower revenue than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than VYNE Therapeutics, indicating that it is currently the more affordable of the two stocks.
83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 1.8% of VYNE Therapeutics shares are held by insiders. Comparatively, 28.4% of Bolt Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
VYNE Therapeutics presently has a consensus target price of $5.75, suggesting a potential upside of 115.36%. Bolt Biotherapeutics has a consensus target price of $7.00, suggesting a potential upside of 455.56%. Given Bolt Biotherapeutics' higher probable upside, analysts plainly believe Bolt Biotherapeutics is more favorable than VYNE Therapeutics.
VYNE Therapeutics has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.
Summary
Bolt Biotherapeutics beats VYNE Therapeutics on 11 of the 16 factors compared between the two stocks.
Get VYNE Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VYNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VYNE Therapeutics Competitors List
Related Companies and Tools
